格卡瑞韦联合匹布他韦治疗12周用于丙型肝炎病毒基因1型感染及既往直接抗病毒治疗失败患者
这项2期开放标签研究(MAGELLAN-1)将50例无肝硬化、既往含直接抗病毒药物方案失败的HCV基因1型感染患者随机分入三组,评估格卡瑞韦联合匹布他韦±利巴韦林治疗12周的疗效与安全性。意向治疗分析中,A、B、C组治疗后第12周持续病毒学应答率分别为100%(6/6)、95%(21/22)和86%(19/22)。作者结论为该联合方案高度有效且耐受良好,联合利巴韦林未提高疗效。
要点
- 无肝硬化、既往DAA治疗失败的HCV基因1型患者中,格卡瑞韦联合匹布他韦12周可获得高持续病毒学应答率。
- A、B、C组SVR12分别为100%(6/6)、95%(21/22)、86%(19/22)。
- 联合利巴韦林未提高疗效,大多数不良事件为轻度。
核心结论
- 格卡瑞韦联合匹布他韦在既往含直接抗病毒药物治疗失败的HCV基因1型感染患者中高度有效且耐受良好,联合利巴韦林未提高疗效。
研究设计与样本
- 2期开放标签研究(MAGELLAN-1),共纳入50例无肝硬化的HCV基因1型感染且既往含直接抗病毒药物方案治疗病毒学失败的患者,随机分入三个治疗组。
主要发现
- A组(格卡瑞韦200 mg联合匹布他韦80 mg)意向治疗分析SVR12为100%(6/6,95%CI 61-100)。
- B组(格卡瑞韦300 mg联合匹布他韦120 mg加利巴韦林800 mg每日一次)意向治疗分析SVR12为95%(21/22,95%CI 78-99)。
- C组(格卡瑞韦300 mg联合匹布他韦120 mg不加利巴韦林)意向治疗分析SVR12为86%(19/22,95%CI 67-95)。
- 病毒学失败A组0例,B组1例,C组1例;C组有2例失访。
- 大多数不良事件为轻度,未观察到与研究药物相关的严重不良事件,丙氨酸氨基转移酶、总胆红素或血红蛋白未见相关实验室异常。
关键数值与推荐
- A组:格卡瑞韦200 mg联合匹布他韦80 mg,SVR12为100%(6/6,95%CI 61-100)。
- B组:格卡瑞韦300 mg联合匹布他韦120 mg加利巴韦林800 mg每日一次,SVR12为95%(21/22,95%CI 78-99)。
- C组:格卡瑞韦300 mg联合匹布他韦120 mg不加利巴韦林,SVR12为86%(19/22,95%CI 67-95)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Although direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high rates of sustained virologic response, virologic failure may still occur, potentially leading to the emergence of viral resistance, which can decrease the effectiveness of subsequent treatment. Treatment options for patients who failed previous DAA-containing regimens, particularly those with nonstructural protein 5A inhibitors, are limited and remain an area of unmet medical need. This phase 2, open-label study (MAGELLAN-1) evaluated the efficacy and safety of glecaprevir (GLE) + pibrentasvir (PIB) ± ribavirin (RBV) in HCV genotype 1-infected patients with prior virologic failure to HCV DAA-containing therapy. A total of 50 patients without cirrhosis were randomized to three arms: 200 mg GLE + 80 mg PIB (arm A), 300 mg GLE + 120 mg PIB with 800 mg once-daily RBV (arm B), or 300 mg GLE + 120 mg PIB without RBV (arm C). By intent-to-treat analysis, sustained virologic response at posttreatment week 12 was achieved in 100% (6/6, 95% confidence interval 61-100), 95% (21/22, 95% confidence interval 78-99), and 86% (19/22, 95% confidence interval 67-95) of patients in arms A, B, and C, respectively. Virologic failure occurred in no patients in arm A and in 1 patient each in arms B and C (two patients were lost to follow-up in arm C). The majority of adverse events were mild in severity; no serious adverse events related to study drug and no relevant laboratory abnormalities in alanine aminotransferase, total bilirubin, or hemoglobin were observed. CONCLUSION: The combination of GLE and PIB was highly efficacious and well tolerated in patients with HCV genotype 1 infection and prior failure of DAA-containing therapy; RBV coadministration did not improve efficacy. (Hepatology 2017;66:389-397).
引用
- Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017. PMID: 28128852. doi:10.1002/hep.29081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。